Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1432-1041
    Keywords: Erythrocytes ; l-Asparaginase ; carrier ; lysedresealed erythrocytes ; pharmacodynamics
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Abstract To evaluate the modification of pharmacodynamic parameters induced by the administration of l-asparaginase loaded into red blood cells, 13 patients received a single dose of l-asparaginase internalised into the carrier. The enzyme was loaded using a reversible lysis-resealing process. The dose per patient ranged from 30 to 200 IU·kg−1. Considerable heterogeneity occurred between patients: the level of l-asparaginase circulating after 24 h represented 47% of the total injected dose as compared to 74.8% for red blood cells (RBCs). However, the half-life of the enzyme remaining in the circulation was very similar to that of the RBC carrier, i.e. 29 days and 27 days, respectively, compared with 8–24 h for the free enzyme. Sustained elimination of plasma l-asparagine occurred, the duration of which was dependent on the injected dose. A single injection of 30·IU·kg−1 was sufficient to eliminate plasma l-asparagine over 10 days. With 150–200 IU·kg−1 the elimination period was extended to 50 days. These data show that the use of RBCs as carriers of l-asparaginase greatly improves the pharmacodynamic parameters of the drug.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1279-8509
    Keywords: Chemotherapy Non-Hodgkin’s lymphoma Elderly
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We evaluated the value of a CHOP-like regimen in the treatment of Non-Hodgkin’s lymphoma (NHL) in elderly patients in which Doxorubicin was replaced by Epiadramycin and Bleomycin was added. One hundred and thirty-four previously untreated intermediate or high-grade NHL aged 60 years or more were included in the study. Two patients were stage II Bulky, 51 stage III and 81 stage IV. Fifty percent of patients presented poor performance status and 79 out of 119 patients had increased LDH level. Complete remission was obtained in 67% of the patients and partial remission in 8%. With a median follow-up of 58 months, the median overall survival was 25 months (95%CI = (18 41)) with a 35% survival rate at 5 years (95%CI = (26 45)). Univariate and multivariate prognostic factor analysis was performed. For overall survival, univariate analysis showed histology, LDH level, performance status and age greater than 70 year old as prognostic factors. Multivariable analysis showed poor performance status and LDH level as prognostic factors of overall survival, independently than being more than 70 year old. For event-free survival and disease-free survival, the only prognostic factor was β2 microglobulin. This study confirms that CHOP-like regimen give about 35% of long-term survivors in the treatment of aggressive non-Hodgkin’s lymphoma in elderly patients and that new therapeutic approaches are needed to improve the prognosis of these patients.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1365-2133
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Summary Primary cutaneous medium and large cell lymphomas (MLCL) other than mycosis fungoides (MF) are rare, and their prognosis and treatment are controversial. The clinical, immunohistological and follow-up data of 54 well-documented cases of primary cutaneous MLCL other than MF, seen in our institutions over a 14-year period, were retrospectively reviewed, in order to determine the prognostic factors related to these lymphomas, and to analyse the results obtained with different treatment regimens. Forty-six patients presented with a solitary tumour or with localized lesions. and eight had disseminated cutaneous lesions. According to the updated Kiel classification, 45 cases (83%) corresponded to B-cell lymphomas: centroblastic lymphomas, 32 cases; centroblastic-centrocytic lymphomas, 11 cases; immunoblastic lymphomas, two cases. Nine cases (17%) were classified as T-cell lymphomas: pleomorphic medium and large cell lymphomas, eight cases; anaplastic large cell lymphoma. one case. Four of eight patients with disseminated skin lesions had a T-cell lymphoma. whereas 41 of 46 patients with a solitary tumour had a B-cell lymphoma. Patients with disseminated skin lesions and elevated serum lactate dehydrogenase (LDH) levels had a poor prognosis. Comparison of patients' overall survival, depending on immunohistological subtype, showed that the median survival of patients with pleomorphic T-cell lymphoma was 2·5 years, whereas it was not reached at 12 years for patients with centroblastic centrocytic and centroblastic lymphoma. The eight patients with disseminated skin lesions were treated with polychemotherapy. Most patients with a solitary tumour or with localized lesions of low tumour bulk were treated by surgical excision or radiotherapy alone, and nine other patients with localized lesions of high tumour bulk were treated with initial polychemotherapy. Clinical presentation (i.e. solitary or disseminated lesions), serum LDH levels, and the immunohistological subtype, are important prognostic factors in cutaneous MLCL. Patients with disseminated skin lesions have a poor prognosis, and should be treated with intensive polychemotherapy regimens, whereas those with a solitary tumour, or with localized lesions of low tumour bulk, are adequately treated by radiotherapy.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1569-8041
    Keywords: CA125 ; LDH ; low-grade ; NHL ; prognostic factor ; serologic index
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background:Serum CA125 (sCA125) was recently reported to be ofclinical value in the staging and follow-up of patients with non-Hodgkin'slymphoma (NHL). This report aims to investigate the prognostic value of a newserologic index combining sCA125 and LDH serum levels. Patients and methods:One hundred thirty-seven patients werestudied, sixty-three with histologically proven low-grade NHL, andseventy-four with a high-grade subtype. Results:sCA125 and LDH levels were elevated in more than onethird of patients. sCA125 was more frequently increased than LDH in low-gradeNHL. In this group, complete remission (CR) was achieved in 87, 45, and0% (P = 〈2 × 10−6) of patientswith normal sCA125 and LDH serum levels (Low-risk group), one parameterincreased (Intermediate-risk group), and increased sCA125 and LDH serum levels(high-risk group), respectively. The estimated five-year overall survival was97%, 67% and 22% for low, intermediate, and high-riskgroups, respectively. This combination was the only parameter predictive ofRFS and OS in multivariate analysis (P 〈 0.0001). Conclusions:In this study the combination of s-LDH and sCA125levels (normal vs. abnormal) was found to be an important prognostic factorin low-grade lymphoma and may be used in the selection of appropriatetherapeutic approaches for individual patients.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...